It is tempting to speculate that a combination of loss of chromosomes 6, 10, and 17 and molecular two-hit disruption of PTEN and TP53 are the main drivers for the loss of CDKN1A expression and worse patient outcomes in chRCC. This evidence concerns the gene TP53 and chromophobe renal cell carcinoma.